VAXART INC. DL-10
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform in the United States. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus v… Read more
VAXART INC. DL-10 (NB11) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, VAXART INC. DL-10 (NB11) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
VAXART INC. DL-10 - Net Assets Trend (None–None)
This chart illustrates how VAXART INC. DL-10's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for VAXART INC. DL-10 (None–None)
The table below shows the annual net assets of VAXART INC. DL-10 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to VAXART INC. DL-10's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
VAXART INC. DL-10 Competitors by Market Cap
The table below lists competitors of VAXART INC. DL-10 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
AptaBio Therapeutics Inc
KQ:293780
|
$92.51 Million |
|
Motrex Co. Ltd
KQ:118990
|
$92.51 Million |
|
TCM Group
CO:TCM
|
$92.54 Million |
|
Telechips Inc
KQ:054450
|
$92.54 Million |
|
Delta Plus Group SA
PA:ALDLT
|
$92.46 Million |
|
VICTORIAN P.G. LS -001
F:637
|
$92.39 Million |
|
Jiangsu GDK Biotechnology Co Ltd
SHG:688670
|
$92.38 Million |
|
Investcorp Europe Acquisition I Corp
NASDAQ:IVCB
|
$92.36 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in VAXART INC. DL-10's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares VAXART INC. DL-10's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently VAXART INC. DL-10 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares VAXART INC. DL-10's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,345,847,517
- Average return on equity (ROE) among peers: -601.64%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| VAXART INC. DL-10 (NB11) | €- | N/A | N/A | $92.50 Million |
| 09R (09R) | $5.86 Million | -145.33% | 0.68x | $12.96 Million |
| IDORSIA AG (19T) | $104.20 Million | -608.99% | 13.23x | $582.75 Million |
| 1S90 (1S90) | $10.78 Million | -2319.92% | 31.35x | $54.21 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.28 Million |
| 25K0 (25K0) | $-79.67 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $508.00K | -2193.11% | 12.24x | $9.80 Million |
| Intervacc AB (publ) (2E9) | $308.25 Million | -9.53% | 0.07x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $3.03 Million | -558.03% | 2.82x | $9.20 Million |
| GNI Group Ltd (3G6) | $13.10 Billion | 1.39% | 0.57x | $772.60 Million |